Launches $100M At-The-Market Offering, Potentially Doubling Shares Outstanding
SXTC sits 34% above its 52-week low of $1.25 on elevated volume (1.9× avg).
Summary
China SXT Pharmaceuticals launched an At-The-Market (ATM) offering to sell up to $100 million in Class A Ordinary Shares, representing a massive potential dilution of over 150% if fully utilized.
Key Events · Financing and Capital Events · SXTC
-
New At-The-Market (ATM) Offering Program
The company has established an ATM program with Univest Securities, LLC, to sell up to $100,000,000 in Class A Ordinary Shares from time to time.
-
Extreme Potential Dilution
If the offering is fully utilized at the assumed price of $1.65 per share, it could result in the issuance of approximately 60.6 million new shares, increasing total outstanding shares by about 158.6% from 38.2 million to 98.8 million.
-
Pricing at Market
Shares will be sold 'at the market' at prevailing prices, with an assumed offering price of $1.65 per share based on the May 29, 2026 closing price.
-
Use of Proceeds
Net proceeds are intended for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.
Analysis · SXTC · Life Sciences
China SXT Pharmaceuticals has initiated a substantial At-The-Market (ATM) offering program, authorizing the sale of up to $100 million in Class A Ordinary Shares. Given the company's current market capitalization of approximately $1.6 million, this program represents an extremely significant potential capital raise that could lead to over 6000% dilution relative to the current market cap. If fully utilized at the recent market price of $1.65 per share, the offering could increase the number of outstanding shares by approximately 158.6%, from 38.2 million to 98.8 million. This follows recent capital raises, including a direct offering in April and a private placement in May, indicating a continuous need for funding. While the capital provides a runway for general corporate purposes, the sheer scale of potential dilution is highly negative for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTC was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $1.25 to $1,046.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.